Lipoic Acid Ocular Compositions for Presbyopia and Cataract
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Age-related physiological changes, such as decreased accommodative amplitude, lead to presbyopia and cataracts, for which existing treatments are inadequate and often toxic to surrounding tissues.
Innovation Solution
A pharmaceutical composition comprising lipoic acid-based active agents, administered via various ocular routes, which reduces disulfide bond formation and oxidative damage, thereby increasing accommodative amplitude and maintaining lens elasticity and reducing opacity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If high doses of conventional treatments are administered to combat presbyopia and cataract, then therapeutic efficacy is improved, but toxicity to surrounding healthy tissues increases
Solution Approach 1:
The patent changes the chemical parameter by using lipoic acid and its derivatives (such as 6,8-dimercaptooctanoic acid, dihydrolipoate) instead of conventional high-dose treatments. This chemical substitution allows achieving therapeutic effects at much lower concentrations (10 μM to 250 μM), thereby resolving the contradiction between efficacy and toxicity
Solution Approach 2:
Lipoic acid acts as an intermediary reducing agent that specifically targets disulfide bonds in lens proteins. This mediator approach allows selective action on the pathological target (oxidized lens proteins) without affecting surrounding healthy tissues, thus achieving high efficacy with minimal toxicity
2Reliability
If existing treatments for presbyopia and cataract are used, then some therapeutic effect is achieved, but the treatments are inadequate and often toxic
Solution Approach 1:
The patent employs lipoic acid-based compounds at optimized low concentrations (10 μM to 250 μM) with specific chemical properties that provide therapeutic effect without toxicity. The use of emulsifiers and buffered carriers further optimizes the delivery parameters to enhance safety and efficacy
Solution Approach 2:
The patent converts the harmful oxidative stress (disulfide bond formation) that causes presbyopia and cataract into a beneficial target for treatment. By using reducing agents that specifically reverse disulfide bonds, the treatment addresses the root cause of the disease while avoiding the toxicity of conventional approaches
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The lipoic acid-based composition effectively increases accommodative amplitude by at least 0.25 diopters and decreases lens opacity, maintaining lens health beyond what is expected in untreated lenses of the same age, with reduced toxicity and dosage compared to previous treatments.
Implementation Method 1
The active agent can be administered to reduce disulfide bond formation and oxidative damage, thereby increasing accommodative amplitude and maintaining lens elasticity
Implementation Method 2
Both presbyopia and cataract are age-related and may share common etiologies such as lens growth, oxidative stress, and/or disulfide bond formation
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Compositions containing low doses of lipoic acid-based active agents and methods for using the same are provided. In particular, compositions containing low dose lipoic acid, lipoic acid derivatives, and lipoic acid seleno-derivatives and are provided to prevent and/or treat ocular diseases.